ExpreS2ion to lead European COVID-19 vaccine consortium for rapid clinical development
Hørsholm, Denmark, February 24, 2020 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that the company will lead a consortium of European expert entities in applying for the EU Horizon 2020 and the Coalition for Epidemic Preparedness Innovations (CEPI) grant calls for COVID-19 (SARS-CoV-2) Coronavirus vaccine development. The consortium includes all the bench-to-bedside expertise required for rapid clinical development of the COVID-19 vaccine that is already under development by ExpreS2ion.The aim of the consortium